Vertex Pharmaceuticals (VRTX) SVP nets 2,195-share sale and 1,809-share RSU grant

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Kristen Ambrose reported several stock transactions involving company common shares. She received a grant of 1,809 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 598 shares were disposed of to cover tax obligations at a price of $483.75 per share, and 1,557 shares were sold in open-market transactions at $489.46 per share. On the following day, she sold an additional 638 shares at $473.68 per share under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, leaving her with 7,750 directly owned shares after these transactions.

Insider Trade Summary

Net Seller: 2,195 shares ($1,064,297)

Net Sell 4 txns

Insider Ambrose Kristen

Role SVP & Chief Accounting Officer

Sold 2,195 shs ($1.06M)

Type	Security	Shares	Price	Value
Sale	Common Stock	638	$473.68	$302K
Grant/Award	Common Stock	1,809	$0.00	--
Tax Withholding	Common Stock	598	$483.75	$289K
Sale	Common Stock	1,557	$489.46	$762K

Holdings After Transaction: Common Stock — 7,750 shares (Direct)

Footnotes (1)

1. Restricted stock unit award that vests in installments beginning on February 20, 2027. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ambrose Kristen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		1,809(1)	A	$0	10,543	D
Common Stock	02/17/2026		F		598	D	$483.75	9,945	D
Common Stock	02/17/2026		S(2)		1,557	D	$489.46	8,388	D
Common Stock	02/18/2026		S(2)		638	D	$473.68	7,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award that vests in installments beginning on February 20, 2027.

2. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kristen Ambrose report for Vertex Pharmaceuticals (VRTX)?

Kristen Ambrose reported a mix of acquisitions and disposals of Vertex common stock. She received a 1,809-share restricted stock unit award, had 598 shares withheld for taxes, and sold 1,557 and 638 shares in separate open-market transactions, all reported as directly held.

How many Vertex (VRTX) shares did Kristen Ambrose sell in these Form 4 transactions?

She sold a total of 2,195 shares of Vertex common stock in open-market transactions. This includes 1,557 shares at $489.46 per share and 638 shares at $473.68 per share, executed under a company-approved Rule 10b5-1 trading plan.

What stock award did Kristen Ambrose receive from Vertex Pharmaceuticals (VRTX)?

She received a restricted stock unit award covering 1,809 shares of Vertex common stock. The award is scheduled to vest in installments beginning on February 20, 2027, aligning ongoing equity compensation with her role as SVP and Chief Accounting Officer at the company.

Why were 598 Vertex (VRTX) shares disposed of in Kristen Ambrose’s Form 4?

The 598 shares were disposed of to satisfy tax obligations using stock rather than cash. The shares were valued at $483.75 per share and the transaction is characterized as payment of tax liability by delivering securities, rather than an open-market sale for investment purposes.

What is the significance of the Rule 10b5-1 trading plan in Kristen Ambrose’s Vertex (VRTX) sales?

The filing states that certain sales were made under a pre-approved Rule 10b5-1 trading plan. This plan, entered on August 8, 2025, automatically schedules trades, helping separate the timing of her stock sales from day-to-day, non-public information she may access in her executive role.

How many Vertex (VRTX) shares does Kristen Ambrose own after these reported transactions?

After the reported transactions, she directly owns 7,750 shares of Vertex common stock. This figure reflects the net result of the restricted stock unit award, the tax-withholding share disposition, and the two open-market sales disclosed in the Form 4 filing.